Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 is a research paper published in Journal of Clinical Oncology (2024). On theSindex it has a DataRank of 0.930. It has been cited 19 times, with 19 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0.481
From 12 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 19 citers.
NCI NIH HHS
Grant: U10 CA180821
NCI NIH HHS
Grant: UG1 CA233178
NCI NIH HHS
Grant: UG1 CA233247
NCI NIH HHS
Grant: U10 CA180794
NCI NIH HHS
Grant: U10 CA180802
NCI NIH HHS
Grant: UG1 CA233196
NCI NIH HHS
Grant: UG1 CA232760
NCI NIH HHS
Grant: UG1 CA233184
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: U24 CA196172
NCI NIH HHS
Grant: UG1 CA239767
NCI NIH HHS
Grant: U10 CA180888
NCI NIH HHS
Grant: UG1 CA189828
FWCI
3.75
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals